Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares, rose in value on Wednesday, July 09, with the stock price up by 3.15% to the previous day’s close as strong demand from buyers drove the stock to $1.31.
Actively observing the price movement in the last trading, the stock closed the session at $1.27, falling within a range of $1.26 and $1.38. The value of beta (5-year monthly) was 1.614. Referring to stock’s 52-week performance, its high was $5.44, and the low was $1.01. On the whole, ZNTL has fluctuated by -13.82% over the past month.
With the market capitalization of Zentalis Pharmaceuticals Inc currently standing at about $94.26 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ZNTL’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ZNTL currently trading nearly -1.58% and -0.73% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.25, while the 7-day volatility ratio is showing 7.74% which for the 30-day chart, stands at 9.08%. Furthermore, Zentalis Pharmaceuticals Inc (ZNTL)’s beta value is 1.69.
A comparison of Zentalis Pharmaceuticals Inc (ZNTL) with its peers suggests the former has fared considerably weaker in the market. ZNTL showed an intraday change of 3.15% in last session, and over the past year, it shrunk by -56.77%%.
Data on historical trading for Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) indicates that the trading volumes over the past 10 days have averaged 1.98 and over the past 3 months, they’ve averaged 999.21K. According to company’s latest data on outstanding shares, there are 71.95 million shares outstanding.
Nearly 22.85% of Zentalis Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 76.44% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.7 million shares as on 2025-06-13, resulting in a short ratio of 6.76. According to the data, the short interest in Zentalis Pharmaceuticals Inc (ZNTL) stood at 989.00 of shares outstanding as of 2025-06-13; the number of short shares registered in 2025-05-15 reached 6.17 million. The stock has fallen by -63.81% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ZNTL stock heading into the next quarter.
